InspireMD (NSPR) Stock Forecast: StockMap's 2-Week Call

NSPR stock forecast: StockMap's model leans Underperform on InspireMD for the two weeks after the Nov 19 close, toward NSPR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 4 two-week windows on NSPR since Sep 24; by chance, a call on the same dates was right 54% of the time.

InspireMD last closed at $0.62, -10.14% on the session.

Against the IVW growth benchmark the position is -7.81% over the forecast window.

InspireMD's market cap is $33.35M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).

Where NSPR sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

31 daily calls for NSPR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks InspireMD in the 8th percentile on return on equity, where 100 is best.

InspireMD is classified under Health Care / Health Care Equipment & Supplies.

StockMap tracks InspireMD as the 115th largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.

On that composite InspireMD ranks 85th of 141 in the group, against a group median of -0.18.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

InspireMD (NSPR) — StockMap 2-week forecast & tracked accuracy